Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Src inhibitors in early breast cancer: a methodology, feasibility and variability study.

Jones RJ, Young O, Renshaw L, Jacobs V, Fennell M, Marshall A, Green TP, Elvin P, Womack C, Clack G, Dixon JM.

Breast Cancer Res Treat. 2009 Mar;114(2):211-21. doi: 10.1007/s10549-008-9997-1. Epub 2008 Apr 14.

PMID:
18409068
2.

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.

Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J, Logie A, Hargreaves J, Hickinson DM, Wilkinson RW, Elvin P, Boyer B, Carragher N, Plé PA, Bermingham A, Holdgate GA, Ward WH, Hennequin LF, Davies BR, Costello GF.

Mol Oncol. 2009 Jun;3(3):248-61. doi: 10.1016/j.molonc.2009.01.002. Epub 2009 Feb 7.

3.

Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.

Rajeshkumar NV, Tan AC, De Oliveira E, Womack C, Wombwell H, Morgan S, Warren MV, Walker J, Green TP, Jimeno A, Messersmith WA, Hidalgo M.

Clin Cancer Res. 2009 Jun 15;15(12):4138-46. doi: 10.1158/1078-0432.CCR-08-3021. Epub 2009 Jun 9.

4.

Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.

Herynk MH, Beyer AR, Cui Y, Weiss H, Anderson E, Green TP, Fuqua SA.

Mol Cancer Ther. 2006 Dec;5(12):3023-31.

5.

PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.

Ma JG, Huang H, Chen SM, Chen Y, Xin XL, Lin LP, Ding J, Liu H, Meng LH.

Breast Cancer Res Treat. 2011 Nov;130(1):85-96. doi: 10.1007/s10549-010-1302-4. Epub 2010 Dec 22.

PMID:
21181437
6.

Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model.

Dong M, Rice L, Lepler S, Pampo C, Siemann DW.

Anticancer Res. 2010 Nov;30(11):4405-13.

PMID:
21115886
7.

CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion.

Baumann P, Thiele W, Cremers N, Muppala S, Krachulec J, Diefenbacher M, Kassel O, Mudduluru G, Allgayer H, Frame M, Sleeman JP.

Cell Mol Life Sci. 2012 Feb;69(3):435-48. doi: 10.1007/s00018-011-0756-9. Epub 2011 Jun 28.

PMID:
21710320
9.

Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.

Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR.

J Clin Endocrinol Metab. 2009 Jun;94(6):2199-203. doi: 10.1210/jc.2008-2511. Epub 2009 Mar 17.

10.

Denbinobin suppresses breast cancer metastasis through the inhibition of Src-mediated signaling pathways.

Chen PH, Peng CY, Pai HC, Teng CM, Chen CC, Yang CR.

J Nutr Biochem. 2011 Aug;22(8):732-40. doi: 10.1016/j.jnutbio.2010.06.004. Epub 2010 Nov 9.

PMID:
21062671
11.

Bombesin and gastrin releasing peptide increase tyrosine phosphorylation of focal adhesion kinase and paxillin in non-small cell lung cancer cells.

Leyton J, Garcia-Marin LJ, Tapia JA, Jensen RT, Moody TW.

Cancer Lett. 2001 Jan 10;162(1):87-95.

PMID:
11121866
12.
13.

Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma.

Madan R, Smolkin MB, Cocker R, Fayyad R, Oktay MH.

Hum Pathol. 2006 Jan;37(1):9-15.

PMID:
16360410
14.

Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.

Cavalloni G, Peraldo-Neia C, Sarotto I, Gammaitoni L, Migliardi G, Soster M, Marchiò S, Aglietta M, Leone F.

Mol Cancer Ther. 2012 Jul;11(7):1528-38. doi: 10.1158/1535-7163.MCT-11-1020. Epub 2012 Mar 27.

15.

CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells.

Chen Q, Manning CD, Millar H, McCabe FL, Ferrante C, Sharp C, Shahied-Arruda L, Doshi P, Nakada MT, Anderson GM.

Clin Exp Metastasis. 2008;25(2):139-48. Epub 2007 Dec 5.

PMID:
18064530
16.

Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells.

Hiscox S, Jordan NJ, Morgan L, Green TP, Nicholson RI.

Clin Exp Metastasis. 2007;24(3):157-67. Epub 2007 Mar 30.

PMID:
17394086
18.

Involvement of focal adhesion kinase in inhibition of motility of human breast cancer cells by sphingosine 1-phosphate.

Wang F, Nohara K, Olivera A, Thompson EW, Spiegel S.

Exp Cell Res. 1999 Feb 25;247(1):17-28.

PMID:
10047444
19.

Crk-associated substrate tyrosine phosphorylation sites are critical for invasion and metastasis of SRC-transformed cells.

Brábek J, Constancio SS, Siesser PF, Shin NY, Pozzi A, Hanks SK.

Mol Cancer Res. 2005 Jun;3(6):307-15.

20.

Angiotensin II induces focal adhesion kinase/paxillin phosphorylation and cell migration in human umbilical vein endothelial cells.

Montiel M, de la Blanca EP, Jiménez E.

Biochem Biophys Res Commun. 2005 Feb 25;327(4):971-8.

PMID:
15652490

Supplemental Content

Support Center